ArticleClinical rheumatology2025
The association between calcium-phosphorus product and hyperuricemia varied in BMI groups: a mediation analysis study.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe relationship between the calcium-phosphorus product (Ca × P) and hyperuricemia (HUA) has not been thoroughly explored. This study sought to investigate this association across BMI groups in US adults.
methodsA cross-sectional analysis was conducted using the 2017-2018 National Health and Nutrition Examination Survey (NHANES) dataset (N = 5068). The association was evaluated through restricted cubic splines, logistic regression, and mediation analysis.
resultsParticipants in the highest quartile of Ca × P had a 1.31-fold higher odds of HUA (OR 1.31; 95% CI 1.04-1.65) compared to those in the lowest quartile. A positive linear association between Ca × P and HUA was observed among overweight or obese individuals (OR 1.04; 95% CI 1.01-1.08 and OR 1.04; 95% CI 1.01-1.06, respectively). In the obese subgroup, those in the highest Ca × P quartile had a 1.50-fold increased odds of HUA (OR 1.50; 95% CI 1.11-2.03). Moreover, serum triglycerides mediated 23.12% of the association between Ca × P and HUA in obese adults, showing differential effect patterns.
conclusionCa × P levels were positively associated with a greater prevalence of HUA, especially in the overweight or obesity population. Serum triglycerides play a crucial mediating role in the relationship between Ca × P and HUA among obese people. Key Points • Elevated per Ca × P level is significantly associated with a 3% increased risk of hyperuricemia among US adults, with individuals in the highest quartile exhibiting 1.31-fold higher odds compared to those in the lowest quartile. • The association between Ca × P and hyperuricemia is notably stronger in overweight and obese populations, with obese adults in the highest Ca × P quartile showing a 1.5-fold increased risk of hyperuricemia. • Serum triglycerides mediate 23.12% of the relationship between Ca × P and hyperuricemia in obese individuals, indicating a substantial metabolic pathway influencing hyperuricemia development in this high-risk group.
Indexed as
Identifiers
41118074What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.